Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.63 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.63 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.60 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.55 |
| ▸ | MEN1 | O00255 | 2/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.55 |
| ▸ | TSHR | P16473 | 2/20 | 0.55 |
| ▸ | ALDH1A3 | P47895 | 1/20 | 0.54 |
| ▸ | MAPT | P10636 | 2/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | RECQL | P46063 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25640341 | 0.99 | KDM4E (0.61) | KDM4ETDP1L3MBTL1RXFP1ALDH1A1 | |
| SCHEMBL24234716 | 0.88 | KDM4E (0.50) | KDM4ETDP1L3MBTL1RXFP1ALDH1A1 | |
| SCHEMBL17982837 | 0.87 | RXFP1 (0.55) | KDM4ETDP1L3MBTL1RXFP1ALDH1A1 | |
| SCHEMBL348999 | 0.87 | MAPT (0.64) | KDM4EL3MBTL1RXFP1ALDH1A1MEN1 | |
| SCHEMBL7359117 | 0.87 | ALDH1A1 (0.58) | KDM4ETDP1L3MBTL1ALDH1A1MEN1 | |
| SCHEMBL29953174 | 0.86 | CYP1A2 (0.57) | KDM4ETDP1L3MBTL1RXFP1ALDH1A1 | |
| SCHEMBL15330421 | 0.84 | RXFP1 (0.52) | KDM4ETDP1L3MBTL1RXFP1ALDH1A1 | |
| SCHEMBL2562461 | 0.82 | MAPT (0.50) | KDM4ETDP1L3MBTL1RXFP1ALDH1A1 | |
| SCHEMBL2556584 | 0.81 | NPC1 (0.50) | KDM4ETDP1L3MBTL1RXFP1ALDH1A1 | |
| SCHEMBL15332886 | 0.81 | RXFP1 (0.52) | KDM4ETDP1L3MBTL1RXFP1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170368051-A1 | 2-PHENETHENYLTETRAHYDRO ISOQUINOLINES USEFUL AS ANTI-HIV COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-12-28 | — | — | US | disclosed |
| WO-2016100391-A1 | 2-PHENETHENYLTETRAHYDRO ISOQUINOLINES USEFUL AS ANTI-HIV COMPOUNDS | Prosetta Antiviral, Inc. (US) | 2016-06-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170368051-A1 | 2-PHENETHENYLTETRAHYDRO ISOQUINOLINES USEFUL AS ANTI-HIV COMPOUNDS | MAVS, EIF2AK2, POLRMT | KDM4E 289/4885TDP1 809/4885L3MBTL1 1140/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.